JonesTrading initiated coverage on Silverback Therapeutics with a new price target
$SBTX
Specialty Chemicals
Consumer Discretionary
JonesTrading initiated coverage of Silverback Therapeutics with a rating of Buy and set a new price target of $50.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2022 | $25.00 → $3.50 | Buy → Neutral | Goldman |
| 4/1/2022 | $25.00 → $1.80 | Outperform → Mkt Perform | SVB Leerink |
| 4/1/2022 | $32.00 → $6.00 | Buy → Hold | Stifel |
| 4/1/2022 | Buy → Neutral | H.C. Wainwright | |
| 11/12/2021 | $42.00 → $25.00 | Outperform | SVB Leerink |
| 8/16/2021 | $46.00 → $49.00 | Outperform | SVB Leerink |
10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
Goldman downgraded Silverback Therapeutics from Buy to Neutral and set a new price target of $3.50 from $25.00 previously
SVB Leerink downgraded Silverback Therapeutics from Outperform to Mkt Perform and set a new price target of $1.80 from $25.00 previously
Stifel downgraded Silverback Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
Transaction to support potential commercialization of neffy™, ARS's needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anap
- Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022 - Silverback to restructure workforce to support prioritized development, reduce operating expense, and extend cash runway - Estimated cash runway extended into the second half of 2026 Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chron
– Proof-of-mechanism established with activation of myeloid and T/NK cells, and evidence of SBT6050 payload localization in the tumor microenvironment – – SBT6050 demonstrated a manageable safety profile with adverse events consistent with on-mechanism immune activation, both as a monotherapy or in combination with pembrolizumab – – Early signals of anti-tumor activity observed in a heavily pre-treated, heterogeneous population – – Management to host conference call today at 6:30 AM ET – Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissu
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverback’s Board of Directors. “On behalf of the board of directors and senior management team at Silverback, I am pleased to welcome Maria to the board,” said Peter Thompson, M.D., Co-founder and Chair of the Silverback Board of Directors. “Maria is an accomplished biopharmaceutical ve
Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that positive clinical data supporting neffy® (previously referred to as ARS-1), the potential first non-injectable medicine for treatment of alle
Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the closing of its merger with Silverback Therapeutics, Inc. (Silverback). This follows the satisfaction of all cus
neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug U
Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the closing of its merger with Silverback Therapeutics, Inc. (Silverback). This follows the satisfaction of all cus
Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date that is anticipated in mid-2023. "The FDA acceptance of our NDA for neffy is a major milestone in our efforts to bring
Gainers AMTD Digital Inc. (NYSE:HKD) climbed 234.7% to settle at $68.00 on Friday amid continued post-IPO volatility. Pagaya Technologies Ltd. (NASDAQ:PGY) shares jumped 118.9% to close at $11.71 on Friday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. AMTD IDEA Group (NYSE:AMTD) gained 103.7% to close at $2.20. The company owns at least 88% stake in recent IPO AMTD Digital. Kidpik Corp. (NYSE:PIK) surged 66.4% to close at $2.48. Yoshitsu Co., Ltd (NASDAQ:TKLF) jumped 48.4% to close at $2.30 after the company announced it will acquire Tokyo Lifestyle Limited for approximately $2.8 million. ToughBuilt Industries, Inc. (NASDAQ:TBLT) rose 39.5% to clo